With so may IOP-lowering drops on the market, it can be challenging to know which is the most appropriate drop to start a patient on for glaucoma.  How does one choose between the variety of prostaglandin analogs, beta blockers, alpha agonists and carbonic anhydrase inhibitors that are available?  When whould one choose monoterapy vs combination therapies?  How do the drops' side effect profiles influence one's first choice on which drop to start?  Glaucoma specialist Dr. Irfan Kherani joins the podcast.

This episode is sponsored by Thea Pharma Canada - https://www.theapharma.ca 

Become a supporter of this podcast: https://www.spreaker.com/podcast/blind-spot-the-eye-doctor-s-podcast--5819306/support.